Financial Performance - Revenue increased by 18.4% from RMB 388.3 million for the year ended December 31, 2024, to RMB 459.9 million for the year ended December 31, 2025[4] - Gross profit turned from a loss of RMB 67.2 million for the year ended December 31, 2024, to a profit of RMB 32.0 million for the year ended December 31, 2025[4] - Net loss decreased by 36.9% from RMB 484.8 million for the year ended December 31, 2024, to RMB 305.8 million for the year ended December 31, 2025[4] - Basic and diluted loss per share improved from RMB 0.62 for the year ended December 31, 2024, to RMB 0.34 for the year ended December 31, 2025[5] - Total revenue for 2025 was RMB 459,922,000, an increase from RMB 388,305,000 in 2024, representing a growth of approximately 18.4%[19] - Revenue from hospital business, including tumor hospitals and clinics, reached RMB 373,257,000 in 2025, up from RMB 271,579,000 in 2024, indicating a growth of about 37.4%[19] - Revenue from the sale and installation of medical equipment and software was RMB 70,214,000 in 2025, down from RMB 99,281,000 in 2024, reflecting a decline of approximately 29.3%[19] - The company reported a loss attributable to owners of RMB 256,603 thousand for 2025, a significant improvement from a loss of RMB 443,223 thousand in 2024, resulting in a basic loss per share of RMB 0.34 compared to RMB 0.62 in the previous year[23] Assets and Liabilities - Total assets decreased from RMB 5,192.9 million in 2024 to RMB 5,117.7 million in 2025[6] - Total liabilities decreased from RMB 4,005.8 million in 2024 to RMB 3,761.6 million in 2025[6] - Equity attributable to owners increased from RMB 1,647.9 million in 2024 to RMB 1,830.3 million in 2025[7] - Cash and cash equivalents increased from RMB 204.5 million in 2024 to RMB 294.5 million in 2025[6] - Trade receivables decreased to RMB 45,807 thousand in 2025 from RMB 51,480 thousand in 2024, with a provision for impairment of RMB 46,401 thousand[24] - Trade payables decreased to RMB 82,699 thousand in 2025 from RMB 112,146 thousand in 2024, indicating improved cash flow management[25] - The net current liabilities as of December 31, 2025, were RMB 576 million, an increase from RMB 422 million as of December 31, 2024, primarily due to the increase in current bank and other borrowings[88] - The total bank borrowings as of December 31, 2025, were RMB 2,712.4 million, up from RMB 1,479.9 million in 2024[85] Operational Focus and Strategy - The company continues to focus on the rental and trade of radiation therapy and imaging diagnostic equipment, as well as providing management and technical services to hospitals[8] - The group has established a light asset business model in the field of tumor treatment and hospital operations, focusing on advanced medical equipment and software services, particularly for healthcare institutions in lower-tier cities[31] - The group is actively seeking additional credit financing and aims to diversify its funding sources by establishing strong relationships with potential investors[18] - The company plans to expand its proton therapy services and deepen AI clinical integration, targeting the Southeast Asian market with a population of approximately 700 million[49] - The company aims to strengthen talent development and research capabilities, collaborating with top medical institutions for specialized training[48] - The company is focusing on building a multi-tiered medical service system to meet urgent clinical needs and enhance service differentiation[47] Research and Development - The group has actively engaged in research, with 14 ongoing projects and 17 published academic papers, enhancing its core competitiveness in proton therapy[35] - The AI medical field achieved a significant breakthrough with the development of the world's first proton therapy vertical domain large language model, enhancing clinical efficiency in treatment identification and personalized plan recommendations[40] - The medical image processing software (HXK-MAICOPPET-1-001) received regulatory approval, enabling precise identification and segmentation of lesions, thus improving diagnostic accuracy and reducing physician workload[41] Cost Management - The group is implementing strict cost control measures, including reducing administrative costs and deferring capital expenditures to maintain liquidity[18] - Administrative expenses decreased by 36.4% from RMB 210.5 million for the year ending December 31, 2024, to RMB 133.8 million for the year ending December 31, 2025, due to cost reduction initiatives[60] - R&D expenses decreased by 9.7% from RMB 31.2 million for the year ending December 31, 2024, to RMB 28.2 million for the year ending December 31, 2025, primarily due to cost efficiency measures[61] Market and Revenue Insights - Hospital business revenue accounted for 81.2% of total revenue in 2025, rising from 69.9% in 2024, with RMB 373.3 million generated[52] - The basic medical insurance fund payment ratio for hospital business decreased to 23% in 2025 from 40% in 2024[45] - The "Shenzhen Huimin Insurance" program was upgraded to include proton therapy coverage, effective from July 1, 2025, allowing for reimbursement at designated medical institutions[46] - The Guangzhou Taihe Tumor Hospital was selected as a designated medical institution under the "Hong Kong-Macao Medical Device Pass" policy, enhancing access to urgently needed medical devices[47] Corporate Governance and Compliance - The company has adopted the corporate governance code and believes it has complied with the code for the year ending December 31, 2025[108] - The audit committee, consisting of three independent non-executive directors, has reviewed the annual performance for the year ending December 31, 2025, and recommended approval to the board[110] - The company has confirmed compliance with the standard code for securities trading by all directors and relevant employees for the year ending December 31, 2025[109] Future Outlook - The company is positioned to capture a trillion-level market share in the oncology treatment sector, driven by the rising global cancer incidence and the demand for intelligent medical solutions[40] - The group anticipates that the application of the new standards will not significantly affect its financial performance and position, except for the impact of Hong Kong Financial Reporting Standard No. 18[11] - A temporary shareholders' meeting is proposed to be held on April 10, 2026, to consider providing guarantees to subsidiaries for financing needs, with a total expected amount not exceeding RMB 3.7 billion[113]

CONCORD HEALTHCARE GROUP CO., LTD. 美中嘉和醫學技術發展集團股份有限公司 （於中華人民共和國註冊成立的股份有限公司） | | | 日期：2026年 月 日 簽署 （附註7） 附註： （股份代號：2453） 與本代表委任表格有關的股 份數目 （附註2） 將於2026年4月10日舉行之臨時股東大會適用之代表委任表格 | 本人╱吾等 | （附註3） | | | --- | --- | --- | | 地址為 | | | | | 乃美中嘉和醫學技術發展集團股份有限公司（「本公司」） | （附註4） 股內資股╱H股 之持有人，茲委任 | | 大會主席或 | | （附註5） | 地址為 為本人╱吾等之代表出席將於2026年4月10日（星期五）上午9時30分（香港時間）假座中國北京市朝陽區光華路7號漢威大廈東區26樓A1室舉行之臨 時股東大會（「臨時股東大會」）或其任何續會，並於該大會或其任何續會上就臨時股東大會通告所載決議案（如下表所示）代表本人╱吾等投票，或如 無任何指示，本人╱吾等的委任代表可酌情投票。 請在欄內填上「✓」），以顯示 閣下投票的表決意向 （附註6） 。 在 閣下委任代 ...

（股份代號：2453） 臨時股東大會通告 茲通告美中嘉和醫學技術發展集團股份有限公司（「本公司」）謹訂於2026年4月10 日（星期五）上午9時30分假座中國北京市朝陽區光華路7號漢威大廈東區26樓A1室舉 行臨時股東大會（「臨時股東大會」），以考慮及酌情通過以下決議案： 除另有指明外，本通告所用詞彙與日期為2026年3月18日的通函所界定者具有相 同涵義。 香港交易及結算所有限公司及香港聯合交易所有限公司對本公告之內容概不負責，對其準確性 或完整性亦不發表任何聲明，並明確表示，概不就因本公告全部或任何部分內容而產生或因倚 賴該等內容而引致之任何損失承擔任何責任。 CONCORD HEALTHCARE GROUP CO., LTD. 美中嘉和醫學技術發展集團股份有限公司 （於中華人民共和國註冊成立的股份有限公司） 附註： 特別決議案 1. 審議及批准關於2026年度向金融機構申請綜合授信額度暨提供擔保的議案。 承董事會命 美中嘉和醫學技術發展集團股份有限公司 董事長兼執行董事 楊建宇 香港，2026年3月18日 – 1 – 1. 有關於臨時股東大會上批准之決議案的詳情，請參閱日期為2026年3月18日的通函（ ...

此乃要件 請即處理 閣下如對本通函任何方面或應採取的行動有任何疑問，應諮詢 閣下的持牌股票經紀或其他註冊證券交易 商、銀行經理、律師、專業會計師或其他專業顧問。 為本公司附屬公司的融資提供擔保及向董事會授權 及 召開臨時股東大會的通告 董事會函件載於本通函第3至6頁。 美中嘉和醫學技術發展集團股份有限公司將於2026年4月10日（星期五）上午9時30分假座中國北京市 朝陽區光華路7號漢威大廈東區26樓A1室召開臨時股東大會（「臨時股東大會」），通告載於本通函第7 頁至第8頁內。隨附於臨時股東大會上使用之代表委任表格。該代表委任表格亦已登載於聯交所網站 ( www.hkexnews.hk )及本公司網站( www.concordmedical.com )。 無論 閣下能否出席臨時股東大會，務請將代表委任表格按其上印列的指示填妥，並盡快交回本公司於香 港的股份過戶登記分處香港中央證券登記有限公司，地址為香港灣仔皇后大道東183號合和中心17M樓， 惟無論如何不遲於臨時股東大會或其任何續會指定舉行日期24小時之前（即2026年4月9日（星期四）上午9 時30分）交回。填妥及交回代表委任表格後，股東仍可依願親身出席臨 ...

CONCORD HEALTHCARE GROUP CO., LTD. 美中嘉和醫學技術發展集團股份有限公司 香港交易及結算所有限公司及香港聯合交易所有限公司對本公告之內容概不負責，對其準確性 或完整性亦不發表任何聲明，並明確表示，概不就因本公告全部或任何部分內容而產生或因倚 賴該等內容而引致之任何損失承擔任何責任。 臨時股東大會及暫停辦理股份過戶登記手續 臨時股東大會預期將於2026年4月10日（星期五）上午九時三十分假座中國北 京市朝陽區光華路7號漢威大廈東區26樓A1室舉行，以考慮及酌情批准(i)提供 擔保及(ii)授權董事會考慮及批准擔保金額範圍內擔保的所有具體事宜。上述 議案的更多詳情、臨時股東大會通告以及相關代表委任表格將於適當時候根據 香港聯合交易所有限公司證券上市規則的規定於香港聯合交易所有限公司網站 ( www.hkexnews.hk )及本公司網站( www.concordmedical.com )刊發及╱或寄發予 股東。 （於中華人民共和國註冊成立的股份有限公司） （股份代號：2453） 為本公司附屬公司的融資提供擔保 及 本公司召開臨時股東大會而暫停辦理股份過戶登記手續 為本公司附屬公司 ...

董事會會議日期 香港交易及結算所有限公司及香港聯合交易所有限公司對本公告之內容概不負責，對其準確性 或完整性亦不發表任何聲明，並明確表示，概不就因本公告全部或任何部分內容而產生或因倚 賴該等內容而引致之任何損失承擔任何責任。 CONCORD HEALTHCARE GROUP CO., LTD. 美中嘉和醫學技術發展集團股份有限公司 （於中華人民共和國註冊成立的股份有限公司） （股份代號：2453） 美中嘉和醫學技術發展集團股份有限公司（「本公司」，連同其附屬公司，統稱「本 集團」）董事（「董事」）會（「董事會」）謹此宣佈，董事會會議將於2026年3月27日 （星期五）舉行，藉以（其中包括）考慮及批准本集團截至2025年12月31日止年度 末期業績及其發佈，並考慮建議派發末期股息（如有）。 承董事會命 美中嘉和醫學技術發展集團股份有限公司 董事長兼執行董事 楊建宇 中華人民共和國北京，2026年3月17日 於本公告日期，董事會包括(i)執行董事楊建宇博士、付驍女士及常亮先生；(ii)非 執行董事王雷先生、宋清寶先生及施波濤先生，及(iii)獨立非執行董事李雪梅女 士、孫延生先生及吳國賢先生。 ...

I. 法定/註冊股本變動 | 1. 股份分類 | 普通股 | 股份類別 | H | | 於香港聯交所上市 (註1) | | 是 | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 證券代號 (如上市) | 02453 | 說明 | | | | | | | | | | 法定/註冊股份數目 | | | 面值 | | 法定/註冊股本 | | | 上月底結存 | | | 313,874,624 | RMB | | 1 RMB | | 313,874,624 | | 增加 / 減少 (-) | | | 0 | | | RMB | | 0 | | 本月底結存 | | | 313,874,624 | RMB | | 1 RMB | | 313,874,624 | | 2. 股份分類 | 普通股 | 股份類別 | 其他類別 (請註明) | | 於香港聯交所上市 (註1) | | 否 | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 證券代號 (如上市) | N/A | 說明 | 內 ...

Business Progress - The subsidiary Guangzhou Taihe Oncology Hospital has been approved to enter the "Hong Kong and Macau Drug and Device Access" list in the Guangdong-Hong Kong-Macao Greater Bay Area, allowing the introduction of innovative oncology drugs and devices that are already approved in Hong Kong and Macau but not yet in mainland China, potentially expanding business boundaries and strengthening competitive advantages [2] Executive Changes - On January 12, 2026, the company announced that Jiang Wei has taken over as president, which may influence the future strategic execution direction [3] Financial Performance - The latest financial report indicates that for the first half of 2025, the company achieved revenue of approximately 200 million, with losses narrowing by 2.9% year-on-year, although revenue decreased by 8.3% year-on-year. The operational commencement of the proton therapy center has improved the hospital business's gross margin, necessitating attention to the sustainability of future profitability [4]

Core Insights - The collaboration between Meizhong Jiahe Group and National Hospital in Indonesia marks a significant milestone in the company's internationalization strategy, focusing on building a comprehensive oncology service center [1] - This partnership aims to address the severe imbalance of high-end medical resources in Southeast Asia, particularly in oncology, by introducing international standards of medical services [3] Group 1: Systematic Solutions - Meizhong Jiahe offers a comprehensive solution that includes advanced technologies such as proton therapy and precision radiotherapy, along with a full chain of support from personalized treatment plans to clinical quality control [4] - The introduction of AI-assisted diagnostic systems will enhance local doctors' efficiency and accuracy, facilitating cross-border medical collaboration through remote consultations and multidisciplinary discussions [4] Group 2: Comprehensive Medical Ecosystem - The collaboration aims to create a "precision and warmth" medical service ecosystem that transitions from a disease-centered approach to a health-centered one, establishing a modern oncology treatment center that integrates diagnosis, treatment, and rehabilitation [6][7] - The initiative includes training local medical professionals through a "sister hospital" model, ensuring sustainable development of international standards in local healthcare [6] Group 3: Global Expansion Strategy - Southeast Asia, with a population of 680 million, presents a significant opportunity for Meizhong Jiahe's global strategy, with the partnership in Indonesia serving as a critical starting point for expanding advanced medical technologies and AI systems across the region [8] - The company's global strategy will unfold in three phases: solidifying regional bases, building a core ecosystem of medical technology and AI, and achieving value co-creation for long-term growth [8] Group 4: Commitment to Patient-Centric Care - The company emphasizes a patient-centered approach, aiming to provide high-quality, precise, and compassionate oncology treatment services locally, thereby reducing the need for patients to seek care abroad [9]

Core Viewpoint - Meizhong Jiahe Medical Technology Development Group has taken a significant step in its international strategy by signing a memorandum of cooperation with National Hospital in Indonesia to establish a comprehensive oncology service center, marking a milestone in the company's globalization efforts and enhancing China's high-end medical technology's international influence [1] Group 1: Strategic Collaboration - The partnership aims to create a high-level oncology diagnosis and treatment service platform in Indonesia, addressing the common issue of cancer medical resource shortages in Southeast Asia and providing a replicable "Indonesian model" [1] - Meizhong Jiahe has developed a comprehensive solution that includes advanced technologies such as proton therapy and precision radiotherapy, along with a full-chain empowerment system covering personalized plan design, equipment optimization, clinical quality control, and standardized treatment processes [2] Group 2: Technological Innovation - The introduction of Meizhong Jiahe's self-developed tumor treatment model and AI-assisted diagnosis system signifies a new phase of intelligent empowerment in the collaboration, enhancing local doctors' diagnostic efficiency and accuracy [2] - The digital platform will facilitate cross-border medical collaboration, enabling real-time cooperation between Meizhong Jiahe's expert team and Indonesian doctors for complex case management [2] Group 3: Sustainable Development - The core of the collaboration is not merely technology transfer but building a comprehensive oncology medical service ecosystem in Indonesia and Southeast Asia, utilizing a "sister hospital" model for deep medical personnel exchanges and training [3] - The globalization strategy will unfold in three phases: solidifying regional footholds, building a core ecosystem of medical technology empowerment and AI-driven services, and achieving value co-creation for long-term growth [3] Group 4: Vision for the Future - The company aims to expand into the Southeast Asian market, focusing on delivering patient-centered care and creating a comprehensive oncology medical ecosystem that encompasses diagnosis, treatment, rehabilitation, and research [4]